Actinium Pharmaceuticals, Inc. - נכסים נקיים למניה בודדת ATNM

Actinium Pharmaceuticals relies on robust patent protections and strict FDA oversight within the radiotherapy sector. The company's book value demonstrates a fundamental margin of safety, where the 0.95 level captures the current state of assets. Development is led by an elite staff of radiopharmaceuticals experts. However, pre-revenue status and testing costs temporarily limit business scaling until licenses are obtained.

An investment audit of the issuer requires an analysis of equity, which in this metric is calculated as the difference between all assets and liabilities divided by the number of shares. For Actinium Pharmaceuticals (ATNM), which is preparing the commercial launch of a radiopharmaceutical through partnerships, information on the book value per share serves as an indicator of the business's material stability during the pre-launch preparation period.